Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
- 15 May 2012
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 39 (8) , 1278-1283
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Glucagon-Like Peptide-1 Versus Somatostatin Receptor Targeting Reveals 2 Distinct Forms of Malignant InsulinomasJournal of Nuclear Medicine, 2011
- Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CTJournal of Nuclear Medicine, 2011
- 68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone ScintigraphyJournal of Nuclear Medicine, 2009
- Chromogranin A‐, serotonin‐, synaptophysin‐ and vascular endothelial growth factor‐positive endocrine cells and the prognosis of colorectal cancer: An immunohistochemical and ultrastructural studyJournal of Gastroenterology and Hepatology, 2008
- Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancerArchives of Gerontology and Geriatrics, 2008
- Psychological Stress Evaluation of Patients with Bronchial Asthma Based on the Chromogranin A Level in SalivaJournal of Asthma, 2008
- Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?Journal of Clinical Oncology, 2007
- Chromogranin A in uremia: Progressive retention of immunoreactive fragmentsKidney International, 1990